<?xml version="1.0" encoding="UTF-8"?>
<p>Demographics and baseline characteristics were generally well balanced across treatment groups, as shown in Table 
 <xref rid="cam41388-tbl-0001" ref-type="table-wrap">1</xref>. Patient ages ranged from 32 to 77 years, with a median of 59 years. Most patients were female (98%) and White (95%), and the majority (84%) had invasive ductal carcinoma. Disease stage at the time of breast cancer diagnosis was Stage II (57%), Stage I (20%), or Stage III (21%), with two patients (1%) diagnosed as Stage IV. Hormone receptor status was positive for 55% of patients (estrogen receptor +/progesterone receptor +), 17% of patients had ER+/PR‐ disease, and 28% of patients had ER‐/PR‐ disease or unknown hormone receptor status. Human epidermal growth factor receptor 2 (HER2) status was positive for 12% of patients, negative for 25% of patients, and unknown for 63% of patients. Most patients (90% overall) had a baseline Eastern Cooperative Oncology Group (ECOG) status of 0, 12 patients (8%) had a performance status of 1, and one patient (1%) had a performance status of 1.
</p>
